Selecta Biosciences Inc expected to post a loss of 1 cent a share - Earnings Preview

Cartesian Therapeutics

01/11/2022 14:00

* Selecta Biosciences Inc  SELB.OQ   SELB.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
3. 
    * The Watertown Massachusetts-based  company is expected to
report
 a 3.2% increase in revenue to $25.214 million from $24.43
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Selecta Biosciences
Inc
is for a loss of 1 cent per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Selecta
Biosciences Inc is $7​, above​ its last closing price of $1.58.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.06       -0.08      0.06      Beat    177.8
 Mar. 31 2022  -0.10       -0.11      0.23      Beat    312.3
 Dec. 31 2021  -0.08       -0.07      0.03      Beat    141.2​
 Sep. 30 2021  -0.03       -0.07      -0.16     Missed  -115.4
 ​​Jun.        -0.13       -0.12      0.04      Beat    134.1
 30 2021                                                
 Mar. 31 2021  -0.10       -0.12      -0.22     Missed  -80.3​
 Dec. 31 2020  -0.09       -0.12      -0.14     Missed  -21
 Sep. 30 2020  0.12        0.06       -0.09     Missed  -250
 This summary was machine generated November 1 at 14:00 GMT.  All
figures in US dollars  unless otherwise stated